Brief: Inozyme Pharma Reports Third Quarter 2020 Financial Results And Provides Business Highlights

Inozyme Pharma

12/11/2020 11:05

Nov 12 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA REPORTS THIRD QUARTER 2020 FINANCIAL
RESULTS AND
PROVIDES BUSINESS HIGHLIGHTS
    * Q3 LOSS PER SHARE $1.55
    * Q3 EARNINGS PER SHARE ESTIMATE $-0.51 -- REFINITIV IBES
DATA
    * SUBMITTED CTA FOR INZ-701 FOR TREATMENT OF ENPP1
DEFICIENCY TO
UNITED KINGDOM REGULATORY AGENCY
    * RECEIVED RARE PEDIATRIC DISEASE AND FAST TRACK
DESIGNATIONS FOR
INZ-701 FOR TREATMENT OF ENPP1 DEFICIENCY
    * EXPECT TO INITIATE INZ-701 PHASE 1/2 CLINICAL TRIALS FOR
ENPP1
AND ABCC6 DEFICIENCIES IN FIRST HALF OF 2021
    * INOZYME PHARMA - EXPECT EXISTING CASH, CASH EQUIVALENTS &
INVESTMENTS SUFFICIENT TO FUND OPERATING EXPENSES & CAPEX
REQUIREMENTS AT LEAST INTO H2 2022

Source text for Eikon:  ID:nGNX4cvp7x 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))